During the last session, Annovis Bio Inc (NYSE:ANVS)’s traded shares were 0.32 million, with the beta value of the company hitting 1.77. At the end of the trading day, the stock’s price was $7.69, reflecting an intraday loss of -6.79% or -$0.56. The 52-week high for the ANVS share is $22.49, that puts it down -192.46 from that peak though still a striking 41.09% gain since the share price plummeted to a 52-week low of $4.53. The company’s market capitalization is $85.90M, and the average intraday trading volume over the past 10 days was 0.31 million shares, and the average trade volume was 1.82 million shares over the past three months.
Annovis Bio Inc (ANVS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. ANVS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.5.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Annovis Bio Inc (NYSE:ANVS) trade information
Annovis Bio Inc (ANVS) registered a -6.79% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.79% in intraday trading to $7.69, hitting a weekly high. The stock’s 5-day price performance is -11.20%, and it has moved by -41.34% in 30 days. Based on these gigs, the overall price performance for the year is -40.98%. The short interest in Annovis Bio Inc (NYSE:ANVS) is 1.54 million shares and it means that shorts have 0.3 day(s) to cover.
The consensus price target of analysts on Wall Street is $26, which implies an increase of 70.42% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $26 and $26 respectively. As a result, ANVS is trading at a discount of -238.1% off the target high and -238.1% off the low.
Annovis Bio Inc (ANVS) estimates and forecasts
Statistics show that Annovis Bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Annovis Bio Inc (ANVS) shares have gone down -29.06% during the last six months, with a year-to-date growth rate more than the industry average at 50.00% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 53.30% this quarter and then jump 78.50% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -126.41%. While earnings are projected to return 73.22% in 2024.
Annovis Bio Inc (NYSE:ANVS)’s Major holders
Annovis Bio Inc insiders own 25.20% of total outstanding shares while institutional holders control 11.58%, with the float percentage being 15.48%. LMR PARTNERS LLP is the largest shareholder of the company, while 43.0 institutions own stock in it. As of 2024-03-31, the company held over 0.83 million shares (or 7.8249% of all shares), a total value of $9.89 million in shares.
The next largest institutional holding, with 0.36 million shares, is of VANGUARD GROUP INC’s that is approximately 3.7577% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $4.26 million.
Also, the Mutual Funds coming in first place with the largest holdings of Annovis Bio Inc (ANVS) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Mar 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 239.51 shares. This amounts to just over 2.14 percent of the company’s overall shares, with a $1.84 million market value. The same data shows that the other fund manager holds slightly less at 101.3, or about 0.91% of the stock, which is worth about $0.78 million.
